-
公开(公告)号：EP1406493A4
公开(公告)日：2006-06-14
申请号：EP02746512
申请日：2002-06-11
申请人： XENOPORT INC
发明人： ZERANGUE NOA , DIAS TRACY , DOWER WILLIAM J
IPC分类号： G01N33/50 , A61K9/22 , A61K38/00 , A61K47/22 , A61K47/42 , A61K47/48 , C07C237/12 , C07C237/20 , C07C317/50 , C07C323/59 , C07C323/60 , C07D207/16 , C07D233/54 , C07K5/02 , C07K5/06 , C12N15/09 , C12Q1/02 , G01N33/15 , G01N33/566 , C07K1/00 , C07K14/00 , C07K16/00 , C07K17/00
CPC分类号： C07D233/64 , A61K38/00 , A61K47/64 , C07C237/12 , C07C237/20 , C07C317/50 , C07C323/59 , C07C323/60 , C07C2601/14 , C07D207/16 , C07K5/0205 , G01N33/566
-
公开(公告)号：EP1651963A2
公开(公告)日：2006-05-03
申请号：EP04756696.3
申请日：2004-07-06
申请人： Xenoport, Inc.
发明人： ZERANGUE, Noa , BHAT, Laxminarayan
IPC分类号： G01N33/574
CPC分类号： C07K14/705 , A61K31/195 , G01N33/5005 , G01N33/5011 , G01N33/6872 , G01N33/84 , G01N2500/00
摘要： MCT1 and MCT4 are expressed at higher levels in many cancer cells than comparable normal cells of the same tissue. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the MCT1 and/or MCT4, as well as inhibitors and substrates of MCT1 and/or MCT4, methods of isolating the same, and methods of using the same for treatment or diagnosis of cancer.
-
13.发明公开BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS 审中-公开二酸衍生物的GALLEN用于改进口服吸收和药物全身生物利用度
公开(公告)号：EP1358200A4
公开(公告)日：2005-07-20
申请号：EP01989083
申请日：2001-10-05
申请人： XENOPORT INC
发明人： GALLOP MARK A , CUNDY KENNETH C
CPC分类号： C07K5/0205 , A61K38/00 , A61K47/54 , A61K47/554 , A61K47/64 , A61K47/65
-
14.发明公开AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES 审中-公开氨基酸共轭导致连续系统浓度的GABA模拟物
公开(公告)号：EP1412324A4
公开(公告)日：2004-09-29
申请号：EP02744288
申请日：2002-06-11
申请人： XENOPORT INC
IPC分类号： C07D295/18 , A61K31/197 , A61K31/198 , A61K31/275 , A61K31/381 , A61K31/40 , A61K31/426 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4453 , A61K31/4458 , A61K31/47 , A61K38/00 , A61K47/48 , A61P1/00 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/32 , A61P29/00 , A61P43/00 , C07C237/12 , C07C237/20 , C07C237/24 , C07C255/58 , C07C317/50 , C07C323/59 , C07C323/60 , C07D207/16 , C07D211/60 , C07D213/53 , C07D213/56 , C07D215/12 , C07D229/02 , C07D233/54 , C07D277/20 , C07D277/30 , C07D333/24 , C07D333/60 , C07K5/02 , G01N33/566
CPC分类号： C07D233/64 , A61K38/00 , A61K47/64 , C07C237/12 , C07C237/20 , C07C317/50 , C07C323/59 , C07C323/60 , C07C2601/14 , C07D207/16 , C07K5/0205 , G01N33/566
-
15.发明公开AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES 审中-公开AMINOSÄUREKONJUGATE，DIE ANHALTENDE SYSTEMISCHE KONZENTRATIONEN VON GABA-ANALOGA ERGEBEN
公开(公告)号：EP1412324A2
公开(公告)日：2004-04-28
申请号：EP02744288.8
申请日：2002-06-11
申请人： Xenoport, Inc.
发明人： GALLOP, Mark, A. , CUNDY, Kenneth, C. , SCHEUERMAN, Randall, A. , BARRETT, Ronald, W. , ZERANGUE, Noa
IPC分类号： C07C261/00
CPC分类号： C07D233/64 , A61K38/00 , A61K47/64 , C07C237/12 , C07C237/20 , C07C317/50 , C07C323/59 , C07C323/60 , C07C2601/14 , C07D207/16 , C07K5/0205 , G01N33/566
摘要： This invention is directed to compounds that provide for sustained systemic concentrations of GABA analogs following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
摘要翻译： 公开了在口服给予动物后提供持续的全身浓度的GABA类似物的化合物。 还公开了药物组合物，以及使用这些化合物的方法。
-
16.发明公开ORALLY ADMINISTERED DOSAGE FORMS OF GABA ANALOG PRODRUGS HAVING REDUCED TOXICITY 审中-公开口服VERABREICHTE DOSIERFORMEN VON GABA-ANALOG-PRODRUGS MIT VERRINGERTERTOXIZITÄT
公开(公告)号：EP1404310A1
公开(公告)日：2004-04-07
申请号：EP02737485.9
申请日：2002-06-11
申请人： Xenoport, Inc.
IPC分类号： A61K31/195
CPC分类号： C07C201/12 , A61K31/19 , A61K31/197 , A61K31/22 , A61K31/27 , A61K31/341 , A61K47/54 , A61K47/555 , C07C271/22 , C07C323/58 , C07C2601/14 , C07D213/79 , C07D213/80 , C07D267/06 , C07D307/33 , C07D307/58 , C07D307/60 , C07D317/32 , C07D317/40 , C07C205/43
摘要： The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs of gabapentin and other GABA analogs that are metabolized to form an aldehyle. The dosage forms of the invention are useful for treating or preventing diseases and/or disorders for which the parent gabapentin or other GABA analog are known to be therapeutically effective.
摘要翻译： 本发明提供GABA类似物的前药，GABA类似物前药的药物组合物和制备GABA类似物前药的方法。 本发明还提供使用GABA类似物前药的方法和使用GABA类似物前药药物组合物治疗或预防常见疾病和/或病症的方法。
-
17.发明公开BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS 审中-公开二酸衍生物的GALLEN用于改进口服吸收和药物全身生物利用度
公开(公告)号：EP1358200A2
公开(公告)日：2003-11-05
申请号：EP01989083.9
申请日：2001-10-05
申请人： Xenoport, Inc.
CPC分类号： C07K5/0205 , A61K38/00 , A61K47/54 , A61K47/554 , A61K47/64 , A61K47/65
摘要： Disclosed are methods for providing enhanced systemic blood concentrations of orally delivered drugs that are incompletely translocated across the intestinal wall of an animal. Also disclosed are methods for the sustained release of drugs, whether poorly or readily bioavailable via oral delivery to animals. Still further, disclosed are compounds and pharmaceutical compositions that are used in such methods.
-
18.发明公开METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS 审中-公开行政单和前药与降低的副作用的方法及其
公开(公告)号：EP2887934A1
公开(公告)日：2015-07-01
申请号：EP13756971.1
申请日：2013-08-22
申请人： XenoPort, Inc.
IPC分类号： A61K31/225 , A61K31/5375 , A61P17/06 , A61P29/00 , A61P25/00 , A61K9/28
CPC分类号： A61K31/225 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K31/5375
摘要： Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
-
19.发明授权Crystalline 1-{[(alpha-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid 有权结晶1 - {[（α-异丁酰氧基乙氧基）羰基]氨基甲基} -1-环己烷乙酸
公开(公告)号：EP2275401B1
公开(公告)日：2013-04-03
申请号：EP10013362.8
申请日：2003-06-11
申请人： XenoPort, Inc.
发明人： Raillard, Stephen P. , Zhou, Cindy X. , Yao, Fenmei , Manthati, Suresh Kumar , Xiang, Jia-Ning , Gallop, Mark A.
IPC分类号： C07C205/00 , C07C261/00 , C07C269/00 , C07C271/00
CPC分类号： C07C271/22 , C07C269/06 , C07C2601/14 , C07D309/06 , C07D335/02
-
公开(公告)号：EP1959948B1
公开(公告)日：2012-07-18
申请号：EP06844799.4
申请日：2006-12-04
申请人： XenoPort, Inc.
发明人： XIANG, Jia-Ning , DAI, Xuedong , ZHOU, Cindy X. , LI, Jianhua , NGUYEN, Mark Q.
IPC分类号： A61K31/24 , C07C229/36 , C07C309/04
CPC分类号： C07C229/36 , C07B2200/07 , C07B2200/13 , C07C229/34 , C07C309/04
摘要： (2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.
-
-
-
-
-
-
-
-
-
搜索结果
100 条记录 (耗时 0.02 秒)
